Min Dong

Publications

1. SLO co-opts host cell glycosphingolipids to access cholesterol-rich lipid rafts for enhanced pore formation and cytotoxicity. mBio. 2025 Jan 21; e0377724. View Abstract
2. C. difficile intoxicates neurons and pericytes to drive neurogenic inflammation. Nature. 2023 Oct; 622(7983):611-618. View Abstract
3. Identification of TFPI as a receptor reveals recombination-driven receptor switching in Clostridioides difficile toxin B variants. Nat Commun. 2022 11 09; 13(1):6786. View Abstract
4. Correction: CDKL3 promotes osteosarcoma progression by activating Akt/PKB. Life Sci Alliance. 2022 Nov; 5(11). View Abstract
5. CRISPR screens in Drosophila cells identify Vsg as a Tc toxin receptor. Nature. 2022 10; 610(7931):349-355. View Abstract
6. Targeted intracellular delivery of Cas13 and Cas9 nucleases using bacterial toxin-based platforms. Cell Rep. 2022 Mar 08; 38(10):110476. View Abstract
7. Emerging enterococcus pore-forming toxins with MHC/HLA-I as receptors. Cell. 2022 03 31; 185(7):1157-1171.e22. View Abstract
8. Knockin mouse models demonstrate differential contributions of synaptotagmin-1 and -2 as receptors for botulinum neurotoxins. PLoS Pathog. 2021 10; 17(10):e1009994. View Abstract
9. Beyond botulinum neurotoxin A for chemodenervation of the bladder. Curr Opin Urol. 2021 03 01; 31(2):140-146. View Abstract
10. Phage-assisted evolution of botulinum neurotoxin proteases with reprogrammed specificity. Science. 2021 02 19; 371(6531):803-810. View Abstract
11. A recurrent, homozygous EMC10 frameshift variant is associated with a syndrome of developmental delay with variable seizures and dysmorphic features. Genet Med. 2021 06; 23(6):1158-1162. View Abstract
12. Delivery of single-domain antibodies into neurons using a chimeric toxin-based platform is therapeutic in mouse models of botulism. Sci Transl Med. 2021 01 06; 13(575). View Abstract
13. The Structure and Classification of Botulinum Toxins. Handb Exp Pharmacol. 2021; 263:11-33. View Abstract
14. A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures. Ann Neurol. 2021 02; 89(2):327-340. View Abstract
15. Genome-Wide CRISPR Screen Identifies Semaphorin 6A and 6B as Receptors for Paeniclostridium sordellii Toxin TcsL. Cell Host Microbe. 2020 05 13; 27(5):782-792.e7. View Abstract
16. Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy. PLoS Biol. 2020 03; 18(3):e3000618. View Abstract
17. Proteomic Analysis Identifies Membrane Proteins Dependent on the ER Membrane Protein Complex. Cell Rep. 2019 09 03; 28(10):2517-2526.e5. View Abstract
18. Sulfated glycosaminoglycans and low-density lipoprotein receptor contribute to Clostridium difficile toxin A entry into cells. Nat Microbiol. 2019 10; 4(10):1760-1769. View Abstract
19. Bioinformatic discovery of a toxin family in Chryseobacterium piperi with sequence similarity to botulinum neurotoxins. Sci Rep. 2019 02 07; 9(1):1634. View Abstract
20. Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models. Sci Adv. 2019 01; 5(1):eaau7196. View Abstract
21. Genetically encoded fluorescent indicators for imaging intracellular potassium ion concentration. Commun Biol. 2019 Jan 14; 2(1):18. View Abstract
22. Genome-wide CRISPR screens for Shiga toxins and ricin reveal Golgi proteins critical for glycosylation. PLoS Biol. 2018 11; 16(11):e2006951. View Abstract
23. Botulinum and Tetanus Neurotoxins. Annu Rev Biochem. 2019 06 20; 88:811-837. View Abstract
24. Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B. Science. 2018 05 11; 360(6389):664-669. View Abstract
25. Crystal Structure of Botulinum Neurotoxin A2 in Complex with the Human Protein Receptor SV2C Reveals Plasticity in Receptor Binding. Toxins (Basel). 2018 04 12; 10(4). View Abstract
26. Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium. Cell Host Microbe. 2018 Feb 14; 23(2):169-176.e6. View Abstract
27. Structural basis for the unique ganglioside and cell membrane recognition mechanism of botulinum neurotoxin DC. Nat Commun. 2017 11 21; 8(1):1637. View Abstract
28. Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin. Nat Commun. 2017 09 04; 8(1):423. View Abstract
29. Identification and characterization of a novel botulinum neurotoxin. Nat Commun. 2017 08 03; 8:14130. View Abstract
30. Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors. Nat Commun. 2017 07 03; 8(1):53. View Abstract
31. Frizzled proteins are colonic epithelial receptors for C. difficile toxin B. Nature. 2016 Oct 20; 538(7625):350-355. View Abstract
32. N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A. Nat Struct Mol Biol. 2016 07; 23(7):656-62. View Abstract
33. Widespread sequence variations in VAMP1 across vertebrates suggest a potential selective pressure from botulinum neurotoxins. PLoS Pathog. 2014 Jul; 10(7):e1004177. View Abstract
34. Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex. Science. 2014 Jun 20; 344(6190):1405-10. View Abstract
35. Cytotoxicity of botulinum neurotoxins reveals a direct role of syntaxin 1 and SNAP-25 in neuron survival. Nat Commun. 2013; 4:1472. View Abstract
36. Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins. J Cell Sci. 2012 Jul 01; 125(Pt 13):3233-42. View Abstract
37. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog. 2011 Mar; 7(3):e1002008. View Abstract
Show All Publications Show Fewer Publications